Invicta Diagnostic Performance Analyzed
Invicta Diagnostic, which offers medical imaging and lab services, started trading on the stock market after its Initial Public Offering (IPO). The stock is currently priced at Rs 95, representing a 11.76% premium to the price it was offered at during the IPO. It initially jumped significantly, reaching Rs 100, but has since paused at its lowest allowed level.
- Invicta’s stock trades at 11.76% over IPO price (Rs 95).
- Initial listing at Rs 100, a 17.65% premium to IPO price.
- Stock momentarily frozen at 5% over listing price.
- IPO heavily subscribed, 4.05 times oversubscribed.
- Raised Rs 6.78 crore from anchor investors pre-IPO launch.
- Funds earmarked for medical equipment and establishing new centers.
The IPO was a success, with investors bidding for 4.05 times more shares than the company offered. Anchor investors contributed Rs 6.78 crore before the IPO even began, buying 7.98 lakh shares at Rs 85 per share. This initial investment was crucial for signaling market confidence.
Invicta Diagnostic provides radiology and pathology services through 7 centers and a central lab, primarily in the Mumbai area. They operate a “hub-and-spoke” system, meaning larger, full-service centers (the ‘hub’) are connected to smaller centers that handle more basic tests (‘spokes’). This spreads their services across a large region.
The company’s recent financial results show a strong performance. They generated Rs 17.08 crore in income and made a profit of Rs 4.08 crore up to September 30, 2025. These numbers demonstrate healthy growth and effective operations.
Investing in healthcare companies like Invicta Diagnostic can be a valuable strategy, considering the growing demand for medical services.
